The use of donor-derived circulating cell free DNA for early detection of rejection and to modulate immunosuppression following liver transplantation: A randomized controlled trial.
Phase 4
- Conditions
- Health Condition 1: K729- Hepatic failure, unspecified
- Registration Number
- CTRI/2023/10/059270
- Lead Sponsor
- Amrita institute of medical sciences and research
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
All Pts admitted to undergo live donor liver transplantation
Exclusion Criteria
1.Multi-organ transplant recipients
2.Those who have undergone dual organ transplant from a single donor
3.Identical twin donor and recipient
4.Pregnant women
5.Patients with leukopenia, leukocytosis & inflammatory illness.
6.Patients who have undergone blood transfusions in the past one month.
7.Those who undergo regular & strenuous physical activity
8.Pts with symptoms of hematoma
9.Pts with middle hepatic venous thrombosis
10.Sepsis
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Detection of allograft rejection with dd-cfDNA in combination with DSA in live donor liver transplant.Timepoint: 7 days, 1 month, 2 months & 4 months post-transplant
- Secondary Outcome Measures
Name Time Method Integrity of liver graft measured with fibroscan, CTMRI or ultrasoundTimepoint: 2 years